Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin

Endocrine Practice

Volumn 13, Issue 5, 2007, Pages 444-450

  Viswanathan, Prabhakar ^a   Chaudhuri, Ajay ^a   Bhatia, Ruchi ^a   Al Atrash, Fida ^a   Mohanty, Priya ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; INSULIN; PEPTIDE; TRIACYLGLYCEROL; VENOM;

ARTICLE; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DRUG COMBINATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

BLOOD PRESSURE; BODY WEIGHT; C-REACTIVE PROTEIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBESITY; PEPTIDES; RETROSPECTIVE STUDIES; TRIGLYCERIDES; VENOMS; WEIGHT LOSS;

EID: 35148814453     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.5.444     Document Type: Article

References (13)

1. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2003;4:401-405.
2. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001;50:583-589.
3. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004;53:2397-2403.
4. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77-88.
5. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (GWAA Study Group). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569.
6. Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial [erratum in Ann Intern Med. 2007;146:896]. Ann Intern Med. 2007;146:477-485.
7. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab. 2004;89:5043-5047.
8. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001;86:1306-1312.
9. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728-2735.
10. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001;86:3257-3265.
11. Aljada A, Friedman J, Ghanim H, et al. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism. 2006;55:1177-1185.
12. Aljada A, Mohanty P, Ghanim H, et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr. 2004;79:682-690.
13. Kumar P, Gangi S, Chaudhuri A, Mohanty P, Dandona P. The Elimination of Diabetic Foot Ulcer and Gangrene in Type 2 Diabetes with Good Glycemic and Cardiovascular Risk Factor Control [abstract P1-607]. Proceedings of Endo 2006, Annual 88th Meeting of the Endocrine Society.